DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The Use of Zoledronic Acid to Complex Regional Pain Syndrome

Information source: University of Sao Paulo General Hospital
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Complex Regional Pain Syndromes

Intervention: Zoledronic acid (Drug); Placebo (Drug)

Phase: Phase 2

Status: Not yet recruiting

Sponsored by: University of Sao Paulo General Hospital

Official(s) and/or principal investigator(s):
Linamara R. Battistella, PHD, Study Director, Affiliation: Centro de Pesquisa Clínica do Instituto de Medicina Física e de Reabilitação do Hospital das Clínicas da FMUSP

Overall contact:
Perola Grinberg Plapler, MD, Phone: 55 11 39058512, Email: perolagp@yahoo.com

Summary

To evaluate the efficacy and the safety of using a single, intravenous 5mg dose of zoledronic acid in managing pain in Complex Regional Pain Syndrome patients.

Clinical Details

Official title: Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient.

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Primary outcome: Pain measured on Visual Analog Scale

Secondary outcome:

Lower Limbs vertical force on Wii platform

American Orthopaedic Foot and Ankle Scale (AOFAS)

36-Item Short Form Health Survey (SF-36)

Detailed description: Complex regional pain syndrome (CRPS) is a disorder of the extremities that is characterized by spontaneous unexplained disproportionate pain, hyperalgesia, swelling, limited range of motion, vasomotor instability, skin changes, and patchy bone demineralization. The incidence of CRPS was estimated to be 5. 46 per 100,000 person years at risk in Olmsted County, Minnesota (US), with a prevalence of 20. 57 per 100,000, while its incidence in the general population of the Netherlands was estimated to be much higher, at 26. 2 per 100,000 person-years. The adverse effects were not serious and lasted just a few days. The beneficial effects of other bisphosphonates have been already documented in several placebo-controlled trials; however, there are no reports on the use of zoledronic acid to reduce pain in CRPS patients.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Patients over 18 years of age of both genders, with continuing pain that is disproportionate to any inciting event, with cardinal features of CRPS.

2. Pain - after initial injury with signs and symptoms present at first visit

3. History of previous unsuccessful treatment for pain, with a minimum of two drug therapies, such as non steroidal anti-inflammatory drugs, steroids, antidepressants, central acting analgesics, calcitonin or sympathetic blocks, (not bisphosphonates) for at least six months. 4. Must report at least one symptom in three of the four following categories: 1. Sensory: Reports of hyperesthesia and/or allodynia 2. Vasomotor: Reports of temperature asymmetry and/or skin color changes and/or skin color asymmetry 3. Sudomotor/Edema: Reports of edema and/or sweating changes and/or sweating asymmetry 4. Motor/Trophic: Reports of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin). 5. Must display at least one sign* at time of evaluation in two or more of the following categories: 1. Sensory: Evidence of hyperalgesia (to pinprick) and/or allodynia (to light touch and/or deep somatic pressure and/or joint movement) 2. Vasomotor: Evidence of temperature asymmetry and/or skin color changes and/or asymmetry 3. Sudomotor/Edema: Evidence of edema and/or sweating changes and/or sweating asymmetry 4. Motor/Trophic: Evidence of decreased range of motion and/or motor dysfunction (weakness, tremor, dystonia) and/or trophic changes (hair, nail, skin). 6. Skin temperature of the affected side equal or higher than on the non-affected side. 7. No other diagnosis better explains the signs and symptoms. Exclusion Criteria: 1. Presence of systemic diseases including diabetes mellitus, hyperthyroidism, renal and liver dysfunction, peripheral vascular or cardiovascular diseases, uncontrolled hypertension, rheumatoid and hematopoietic diseases, neurological diseases not related to CRPS, overt alcohol addiction, positive pregnancy test and/or lactating women, hyperparathyroidism, and hypocalcaemia. 2. Creatinine clearance <35mL/min, with serum creatinine measured before the dose of zoledronic acid. 3. Pre-existing hypocalcaemia and disturbance of mineral metabolism (e. g. hyperparathyroidism, thyroid surgery, parathyroid surgery, malabsorption syndromes, and excision of small intestine). 4. Hypersensitivity to zoledronic acid or any component drugs used in the trial. 5. Patients with asthma and aspirin-sensitivity 6. Pregnancy or unwillingness to use contraceptive methods during the trial 7. Patients who have previously used any kind of bisphosphonate, especially zoledronic acid. 8. Osteoporosis

Locations and Contacts

Perola Grinberg Plapler, MD, Phone: 55 11 39058512, Email: perolagp@yahoo.com

Centro de Pesquisa Clínica do Instituto de Medicina e Reabilitação do HCFMUSP, São Paulo 05716-150, Brazil; Not yet recruiting
Pérola G Plapler, MDPhD, Phone: 55 11 39058512, Email: perolagp@yahoo.com
Marta Imamura, MDPhD, Phone: 55 11 39058512, Email: martaimf3@gmail.com
Pérola G. Plapler, MDPhD, Principal Investigator
Additional Information

Starting date: December 2013
Last updated: February 8, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017